Logo image of KLTO

KLOTHO NEUROSCIENCES INC (KLTO) Stock Fundamental Analysis

NASDAQ:KLTO - Nasdaq - US49876K1034 - Common Stock - Currency: USD

0.189  +0.01 (+5%)

Premarket: 0.1832 -0.01 (-3.07%)

Fundamental Rating

0

Overall KLTO gets a fundamental rating of 0 out of 10. We evaluated KLTO against 561 industry peers in the Biotechnology industry. KLTO has a bad profitability rating. Also its financial health evaluation is rather negative. KLTO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KLTO has reported negative net income.
KLTO had a negative operating cash flow in the past year.
KLTO Yearly Net Income VS EBIT VS OCF VS FCFKLTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -2M -4M -6M

1.2 Ratios

The Return On Assets of KLTO (-250.28%) is worse than 92.87% of its industry peers.
The Return On Equity of KLTO (-518.88%) is worse than 79.50% of its industry peers.
Industry RankSector Rank
ROA -250.28%
ROE -518.88%
ROIC N/A
ROA(3y)-80.77%
ROA(5y)N/A
ROE(3y)-168.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KLTO Yearly ROA, ROE, ROICKLTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KLTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLTO Yearly Profit, Operating, Gross MarginsKLTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, KLTO has more shares outstanding
The debt/assets ratio for KLTO is higher compared to a year ago.
KLTO Yearly Shares OutstandingKLTO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
KLTO Yearly Total Debt VS Total AssetsKLTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.45, we must say that KLTO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.45, KLTO is not doing good in the industry: 78.07% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.23 indicates that KLTO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.23, KLTO is doing worse than 70.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -11.45
ROIC/WACCN/A
WACCN/A
KLTO Yearly LT Debt VS Equity VS FCFKLTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

KLTO has a Current Ratio of 0.13. This is a bad value and indicates that KLTO is not financially healthy enough and could expect problems in meeting its short term obligations.
KLTO has a Current ratio of 0.13. This is amonst the worse of the industry: KLTO underperforms 97.15% of its industry peers.
KLTO has a Quick Ratio of 0.13. This is a bad value and indicates that KLTO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of KLTO (0.13) is worse than 96.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
KLTO Yearly Current Assets VS Current LiabilitesKLTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

KLTO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -405.93%.
EPS 1Y (TTM)-405.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-675%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLTO Price Earnings VS Forward Price EarningsKLTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KLTO Per share dataKLTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KLTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KLOTHO NEUROSCIENCES INC

NASDAQ:KLTO (5/22/2025, 8:19:30 PM)

Premarket: 0.1832 -0.01 (-3.07%)

0.189

+0.01 (+5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners9.71%
Inst Owner Change-15.91%
Ins Owners24.35%
Ins Owner ChangeN/A
Market Cap5.39M
AnalystsN/A
Price TargetN/A
Short Float %0.23%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.55
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0
BVpS0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -250.28%
ROE -518.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.77%
ROA(5y)N/A
ROE(3y)-168.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z -11.45
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-405.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-675%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-323.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-133.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.35%
OCF growth 3YN/A
OCF growth 5YN/A